This mechanism emphasizes the therapeutic potential of targeting STEEP-STING interactions to manage STING-driven inflammatory disorders such as SAVI and systemic lupus erythematosus (SLE) [84]. This evidence concerns the gene STING1 and STING-associated vasculopathy with onset in infancy.